Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADS-5102 (Amantadine HCl) Extended Release in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia
2014-003738-24Phase 3Completed
- Sponsor
- Adamas Pharmaceuticals, Inc.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in levodopa-induced dyskinesia (LID) and Parkinson's disease (PD) comparing ADS-5102 340 mg once nightly with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in UDysRS total score. Started Jan 2015; status: completed.
02
Drugs
amantadine
03
Conditions
levodopa-induced dyskinesia (LID)Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-003738-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003738-24.